Invention Grant
US09586916B2 Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3
有权
用于靶向递送至表达α-V-β-3的细胞的整联蛋白拮抗物缀合物
- Patent Title: Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3
- Patent Title (中): 用于靶向递送至表达α-V-β-3的细胞的整联蛋白拮抗物缀合物
-
Application No.: US14374680Application Date: 2013-01-22
-
Publication No.: US09586916B2Publication Date: 2017-03-07
- Inventor: Robert Alan Goodnow, Jr. , Matthew Michael Hamilton , Agnieszka Kowalczyk , Achyutharao Sidduri
- Applicant: Hoffmann-La Roche Inc.
- Applicant Address: US NJ Nutley
- Assignee: HOFFMANN-LA ROCHE INC.
- Current Assignee: HOFFMANN-LA ROCHE INC.
- Current Assignee Address: US NJ Nutley
- International Application: PCT/EP2013/051082 WO 20130122
- International Announcement: WO2013/110578 WO 20130801
- Main IPC: C07D207/452
- IPC: C07D207/452 ; C07D239/14 ; C07D417/12 ; C07D277/593 ; C07C327/32 ; A61K47/48 ; C07C237/52
Abstract:
The invention relates to compounds of formula (I): wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula (I) for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to alpha-V-beta-3 integrin antagonists to target cells expressing alpha-V-beta-3.
Public/Granted literature
- US20150038523A1 INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 Public/Granted day:2015-02-05
Information query
